Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry - Takeaways - MDSpire

Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry

  • By

  • Pedro Horna

  • Matthew J. Weybright

  • Mathieu Ferrari

  • Dennis Jungherz

  • YaYi Peng

  • Zulaikha Akbar

  • F. Tudor Ilca

  • Gregory E. Otteson

  • Jansen N. Seheult

  • Janosch Ortmann

  • Min Shi

  • Paul M. Maciocia

  • Marco Herling

  • Martin A. Pule

  • Horatiu Olteanu

  • February 29, 2024

  • 0 min

Share

  • 1

    Dual staining for TRBC1 and TRBC2 enhances the identification of T-cell neoplasms, similar to B-cell clonality assessment with light chains.

  • 2

    The anti-TRBC2 antibody was engineered to provide specificity for TRBC2, improving diagnostic accuracy for T-cell malignancies.

  • 3

    Traditional methods for diagnosing T-cell neoplasms face challenges due to overlapping atypical T-cell populations in reactive conditions.

  • 4

    Flow cytometry using TRBC1 and TRBC2 antibodies allows for confident determination of T-cell clonality and targetable isoform expression.

  • 5

    This study demonstrates the effectiveness of TRBC dual staining in clinical diagnostics, addressing limitations of previous T-cell analysis methods.

Original Source(s)

Dual T-cell constant β chain (TRBC)1 and TRBC2 staining for the identification of T-cell neoplasms by flow cytometry

  • by Pedro Horna, Matthew J. Weybright, Mathieu Ferrari, Dennis Jungherz, YaYi Peng, Zulaikha Akbar, F. Tudor Ilca, Gregory E. Otteson, Jansen N. Seheult, Janosch Ortmann, Min Shi, Paul M. Maciocia, Marco Herling, Martin A. Pule, Horatiu Olteanu

  • February 29, 2024

Related Content

Half a century of healing: celebrating the 50th anniversary of EBMT

Refining CAR-NK Design

Preclinical findings suggest that receptor design and timed kinase inhibition could help strengthen next-generation cell therapies.

  • March 4, 2026

  • 2 min
Dana-Farber Cancer Institute and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center recognized for exceptional outcomes in donor stem cell transplants

Dana-Farber Cancer Institute’s adult stem cell transplant program and Dana-Farber/Boston Children’s Cancer and Blood Disorders Center’s pediatric stem cell transplant program have once again received exceptional ratings from the Center for International Blood & Marrow Transplant Research (CIBMTR), earning a +1 performance score, the highest possible designation, on their annual center-specific survival reports.

  • by

  • December 17, 2025

  • 4 min